AUROBINDO

August 5, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 **Company Code No. 524804**

Dear Sir / Madam,

Sub: Proposal of merger of the step-down subsidiaries with wholly owned subsidiary of the Company

We would like to inform you that a proposal to file a Scheme of Amalgamation for merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited, two step-down wholly owned subsidiaries of the Company, with Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company, with Hon'ble NCLT, Hyderabad, has been approved by the Board of Directors of the respective companies and also the Company.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as **Annexure.**

The Board meeting commenced at 4:00 p.m. and concluded at 6.30 p.m.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.05 19:59:35 +05'30'

B. Adi Reddy
Company Secretary

Encl.: Annexure

(CIN : L24239TG1986PLC015190)
AUROBINDO PHARMA LIMITED
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 23736370/23747340 Fax: +91 40 23741080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com

AUROBINDO

Annexure

a) Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc.;	Eugia Pharma Specialities Limited (Eugia Pharma), a wholly owned subsidiary of the Company, is the transferee company which was incorporated in India on April 17th, 2013. Eugia Steriles Private Limited (Eugia Steriles), a wholly owned stepdown subsidiary of the Company, is the transferor company 1, which was incorporated in India on July 5th, 2020. Eugia SEZ Private Limited (Eugia SEZ), a wholly owned step-down subsidiary of the Company, is the transferor company 2, which was incorporated in India on February 20th, 2021. All the above companies are engaged in manufacturing injectable pharmaceutical products. The turnover of Eugia Pharma, Eugia Steriles and Eugia SEZ for the financial year ended March 31st 2026 is as under: Name of the company — Turnover for FY 2026 (INR million) Eugia Pharma — 27,259.04 Eugia Steriles — 62.7 Eugia SEZ — 4,874.2
b) Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	Yes, the transaction is between two step-down subsidiaries and a wholly owned subsidiary of the Company. As per the provisions of Section 188 of Companies Act, 2013 and Regulation 23(5)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, provisions relating to related party transactions are not applicable in respect of transactions among wholly owned subsidiaries and their holding Company.
c) Area of business of the entity(ies);	All three companies are engaged in the business of manufacturing injectable pharmaceutical products.
d) Rationale for amalgamation/ merger	The proposed amalgamation will simplify the existing group structure by consolidating three companies carrying on substantially similar businesses into a single legal entity. The amalgamation shall lead to elimination of corporate and administrative functions and overheads, cost reduction, better treasury management, synergy benefits etc.
e) In case of cash consideration – amount or otherwise share exchange ratio;	No consideration since the proposed merger is between two wholly owned subsidiaries and their holding company.
f) Brief details of change in shareholding pattern (if any) of listed entity.	Not applicable. The Company is not a party to the Scheme of Amalgamation and the shareholding pattern of the Company remains unchanged.

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.05 20:00:01 +05'30'

AUROBINDO PHARMA LIMITED
(CIN : L24239TG1986PLC015190)
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana, India Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com